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Abstract
Bmi-1, a polycomb transcriptional repressor, is implicated in cell cycle regulation and cell senescence. Its absence results in
generalized astrogliosis and epilepsy during the postnatal development, but the underlying mechanisms are poorly
understood. Here, we demonstrate the occurrence of oxidative stress in the brain of four-week-old Bmi-1 null mice. The
mice showed various hallmarks of neurodegeneration including synaptic loss, axonal demyelination, reactive gliosis and
brain mitochondrial damage. Moreover, astroglial glutamate transporters and glutamine synthetase decreased in the Bmi-1
null hippocampus, which might contribute to the sporadic epileptic-like seizures in these mice. These results indicate that
Bmi-1 is required for maintaining endogenous antioxidant defenses in the brain, and its absence subsequently causes
premature brain degeneration.
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Introduction
Bmi-1 is a member of the Polycomb family of transcriptional
repressors. It is implicated in cell cycle regulation and cell
senescence by repression of Ink4a/Arf locus, encoding cell cycle
regulators p16Ink4a and p19Arf [1,2,3,4,5,6]. Furthermore, a
recent study has revealed that Bmi-1 regulates mitochondrial
function, reactive oxygen species (ROS) levels and activation of the
DNA damage response pathway [7].
In the central nervous system (CNS), Bmi-1 protein is localized
within neural stem cells (NSCs), as well as mature neurons and
astrocytes, indicating a critical role in brain development and
maintenance [8,9,10]. Several in vitro and vivo studies have
demonstrated that Bmi-1 regulates NSC proliferation and self-
renewal [11,12,13,14,15]. Bmi-1 null (Bmi-1
2/2) mice exhibit
smaller brains with profound defects in cerebellar growth after 2
weeks of age [16]. Moreover, Bmi-1
2/2 mice develop generalized
astrogliosis, progressive ataxia and epilepsy in the first month after
birth, but the underlying mechanisms are poorly understood
[10,16,17].
The brain is particularly vulnerable to oxidative stress due to its
high metabolic rate, high lipid content and limited antioxidant
defenses [18,19,20]. Therefore, we propose that absence of Bmi-1
causes brain oxidative stress, which may be a primary mechanism
for premature neurodegeneration. In addition, it is known that
astrocytes are responsible for modulation of neurotransmitter
release and synchronization of neuronal firing [21,22]. Reactive
astrocytes accompanied with alterations in glutamate transporters
and glutamine synthetase have been observed in the brains of
patients with temporal lobe epilepsy and animal models of epilepsy
[23,24]. Thus, an additional aim of the present study is to
determine whether there are altered expressions of markers for
glutamate uptake and conversion in the brain of Bmi-1
2/2 mice.
Results
Oxidative stress in Bmi-1 null brain
Bmi-1 is implicated in maintaining the redox homeostasis in
bone marrow cells and freshly isolated thymocytes [7]. To
demonstrate whether deletion of Bmi-1 results in brain oxidative
stress, we collected brain homogenate samples of 4-week-old Bmi-
1
2/2 mice and wild-type (WT) controls and measured hydroxyl
radical, protein carbonyl and malondialdehyde levels, markers of
oxidative damage in DNA, proteins and lipids, respectively. Our
results showed that each oxidative marker increased in the Bmi-1
null brain compared with WT control (Figure 1). Further
experiments revealed a significant elevation of hydroxyl radical
levels but not protein carbonyl and malondialdehyde in the brain
of 2-week-old Bmi-1
2/2 mice (Figure S1). These results indicate
that oxidative DNA damage is an early event in the pathogenesis
of neurodegeneration.
Impairment of neuronal elements in Bmi-1 null
hippocampus
Hippocampal neurons are highly sensitive to various oxidative
insults [18]. We addressed the influence of Bmi-1 deletion on the
degeneration of hippocampal neurons. We performed immuno-
staining for caspase-3 to determine apoptotic neurons, b-tubulin
III for neurites, and anti-synaptophysin to determine the
presynaptic terminals (Figure 2A). Four-week-old Bmi-1
2/2 mice
showed a slightly higher ratio of apoptotic neurons to total neurons
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Conversely, immunoreactive levels of b-tubulin III and synapto-
physin were dramatically decreased in the Bmi-1 null hippocam-
pus (Figure 2C–D).
Ultrastructural analysis further demonstrated the occurrence of
neurodegeneration in the hippocampus of Bmi-1
2/2 mice.
Swollen or vacuolar mitochondria were present at all neural
elements including neuronal somas, dendrites, axonal terminals
and astrocyte processes. Most of synapses underwent degeneration
(Figure 3B). In addition, microvasculature exhibited considerable
dilatation and distortion. Some astrocyte endfeet were highly
swollen with large perivascular vacuoles (Figure 3D). These
pathological alterations were not observed in WT mice
(Figure 3A and C).
Demyelination in Bmi-1 null brain
Oligodendrocytes are also highly sensitive to oxidative stress
[25]. The striatum was selected to investigate the influence of
Bmi-1 deletion on axonal demyelination. Both toluidine blue
histochemistry (Figure 4B) and myelin basic protein (MBP)
immunohistochemistry (Figure 4D) revealed that approximately
1/3 of the fiber bundles exhibited vacuolation in the striatum of
4-week-old Bmi-1
2/2 mice (3564.8% vs. 0% in WT mice, n=5
in each genotype). Electron microscopy further confirmed axonal
demyelination accompanied with spongy degeneration in the
Bmi-1 null striatum (Figure 4F). These pathological changes were
not observed in the striatum of WT littermates (Figure 4A, C and
E). Moreover, no vacuolation changes of fiber bundles were
detected in the striatum of 2-week-old Bmi-1
2/2 mice, indicating
that the process of demyelination is gradual and progressive
(Figure S2).
Reactive gliosis in Bmi-1 null brain
Reactive gliosis is a pathological hallmark in neurodegenerative
and demyelinating diseases [22,26,27]. Therefore, we observed
activation of astrocytes and microglia in the striatum and
hippocampus. Semi-quantitative immunohistochemistry revealed
that the number of glial fibrillary acidic protein (GFAP) positive
astrocytes significantly increased in the striatum and hippocampus
of 4-week-old Bmi-1
2/2 mice compared with WT controls
(Figure 5A–C). Characterized by hypertrophy of cell bodies and
marked upregulation of GFAP expression, a large number of
activated astrocytes were observed. Consistently, Western blot
analysis revealed increased expression levels of GFAP in the
striatum and hippocampus of Bmi-1
2/2 mice (Figure 5D).
Similarly, immunohistochemistry for ionized calcium-binding
adapter molecule (Iba-1) showed that activated microglial cells
were extensively distributed in the striatum and hippocampus of
Bmi-1
2/2 mice, but not WT controls (Figure 6).
Decreased expression of glutamate transporters and
glutamine synthetase in Bmi-1 null hippocampus
Bmi-1
2/2 mice have sporadic epileptic-like seizures and
tremors, but the underlying mechanisms need further investigation
[16,17]. Emerging evidence reveals a critical role of astrocyte
dysfunction, including altered glutamate uptake and conversion in
the pathogenesis of epilepsy [23,24]. Thus, we investigated the
expression levels of glutamate transporter 1 (GLT-1), glutamate/
Figure 1. Brain oxidative stress in 4-week-old Bmi-1
2/2 mice. Brain tissues from Bmi-1
2/2 mice showed higher levels of hydroxyl radical
(120.82614.72 vs. 69.41610.04 U/mg protein; A), protein carbonyl (8.3761.41 vs. 3.8661.09 nmol/mg protein; B) and malondialdehyde (5.3460.45
vs. 4.0360.41 nmol/mg protein; C) than those from WT controls. Five mice per genotype and 3 independent experiments for each homogenized
brain sample. Data are expressed as mean 6 SEM. *P,0.05 vs. WT mice.
doi:10.1371/journal.pone.0032015.g001
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the hippocampus, a key region associated with seizure occurrence
in rodents. Four-week-old Bmi-1
2/2 mice showed decreased
GLT-1, GLAST and GS protein levels, as revealed by both
immunohistochemistry (Figure 7A–B) and Western blot analysis
(Figure 7C). Supplemental data revealed that these markers were
not altered in the hippocampus of 2-week-old Bmi-1
2/2 mice
compared with WT littermates, indicating that glutamate uptake
and conversion impairment is due to oxidative stress rather than
retardation in astrocyte maturation (Figure S3).
Discussion
Bmi-1 is essential for the maintenance and self-renewal of both
hematopoietic and neural stem cells, primarily via the Ink4a
locus encoding p16Ink4a/p19Arf [10,11,12,13,14,15,28,29,30,31].
However, deletion of both Ink4a and Arf fails to rescue the growth
retardation or improve overall survival of Bmi-1
2/2 mice,
indicating that additional Bmi-1-regulated pathways may exist
[15,32,33]. Furthermore, evidence from recent literature suggests
that Bmi-1 is necessary for cellular oxidative metabolism. Liu and
colleagues (2009) have demonstrated that Bmi-1 regulates
mitochondrial function, ROS levels and the DNA damage
response pathway in cultured bone marrow cells and in freshly
isolated thymocytes, independent of the Ink4a/Arf pathway [7].
Treatment with the antioxidant N-acetylcysteine or disruption of
the DNA damage response pathway by Chk2 deletion can
partially rescue various abnormalities including the neurological
defects in Bmi-1
2/2 mice [7]. Another recent study has also
revealed that Bmi-1 regulates antioxidant defenses in cultured
cortical neurons by repressing p53 pro-oxidant activity [8]. The
present results have shown that Bmi-1 absence results in brain
oxidative damage during the postnatal development. This finding
provides insight into the function of Bmi-1 in regulating brain
antioxidant defense and controlling of the normal lifespan of brain
cells.
Pathological analysis on the hippocampus of 4-week-old Bmi-
1
2/2 mice indicates that deterioration of neurons is more
prominent on axonal terminals than cell bodies. This pattern of
neuronal degeneration is consistent with the viewpoint that long,
extended axons and their synapses seem to be more vulnerable in
an oxidative environment due to a high metabolic rate and low
antioxidant defenses at synaptic terminals compared with neuronal
soma [34]. Oxidative stress also plays a critical role in
demyelinating diseases such as multiple sclerosis [25]. We found
that absence of Bmi-1 causes extensive demyelination in the
striatum at 4 weeks after birth. The widespread degeneration and
demyelination leads to severe reactive gliosis, which in turn may
Figure 2. Degeneration of neuronal elements in the hippocampus of 4-week-old Bmi-1
2/2 mice. (A) Immunostaining for caspase-3,
b-tubulin III and synaptophysin. Arrowheads showing apoptotic pyramidal neurons which contained dense caspase-3 immunostaining.
Immunoreactivities of b-tubulin III and synaptophysin were decreased in the Bmi-1 null hippocampus. (B–D) There were a higher ratio of apoptotic
neurons to total neurons (0.03160.004 vs. 0.01960.003; B) and lower mean integrated optical densities (MIOD) of immunostainings for b-tubulin III
(0.6660.07 vs. 160.08; C) and synaptophysin (0.7560.08 vs. 160.12; D) in the hippocampus of Bmi-1
2/2 mice compared with WT controls. Five mice
per genotype and 3 sections per mouse. Data are expressed as mean 6 SEM. *P,0.05 vs. WT mice.
doi:10.1371/journal.pone.0032015.g002
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exacerbates the Bmi-1 absence-induced oxidative damage.
In contrast to neurons and oligodendrocytes undergoing cellular
loss or degeneration, astrocytes exhibit activation and prolifera-
tion, termed ‘‘reactive astrogliosis’’, in response to a variety of
CNS injuries including oxidative damage [22]. We have
demonstrated that reactive astrogliosis occurs in 4-week-old Bmi-
1
2/2 brain and is more serious in the white matter than in the
gray matter. Furthermore, apart from increased GFAP expression,
alterations of astrocyte markers including GLT1, GLAST and GS
are observed, but these changes have not detected at 2 weeks after
birth. These results suggest that reactive astrogliosis is neither an
all-or-none response nor a single uniform process. Instead, reactive
astrogliosis is a finely gradated continuum of progressive changes
in gene expression and cellular morphology [22].
Astrocytes are more resistant to oxidative damage than neurons
and oligodendrocytes because they contain a variety of antioxi-
dants, vitamins and oxidative defense enzymes [35,36,37].
However, sustained oxidative stress also impairs cellular structures
and functions of astrocytes [38]. Glutamate transporters and GS
seem to be highly susceptible to oxidative damage [39,40,41].
Decreased expressions of glutamate transporters and GS have
been observed in postmortem hippocampal tissues from epile-
ptic patients, as well as from animal models of epilepsy
[42,43,44,45,46]. Thus, decreased GS, GLT1 and GLAST would
hamper glutamate clearance and conversion, subsequently exac-
erbating glutamate-mediated neurotoxicity. This may represent
a plausible mechanism for sporadic epileptic-like seizures in
Bmi-1
2/2 mice.
Additionally, impaired glutamate conversion in astrocyte
processes would result in intracellular hyperosmotic pressure, thus
drawing additional water into the astrocytes and causing their
perivascular endfeet to swell, as demonstrated by electron
microscopy. Astrocyte endfeet, one component of the blood-brain
barrier, serve as the first line of defense in response to a variety of
toxic agents in the blood stream [21]. Highly swollen endfeet may
fail to protect the brain parenchyma from toxic substances found
in the circulatory system, which in turn exacerbates neuropath-
ological impairment in Bmi-1
2/2 brain.
In conclusion, we have demonstrated that the polycomb group
protein Bmi-1 is necessary for regulating endogenous antioxidant
defenses in the brain, and its absence causes oxidative damage in
the premature mouse brain. Bmi-1
2/2 mice may serve as a
suitable model for preclinical evaluation of the neuroprotective
efficacy of antioxidant agents.
Materials and Methods
Mice and genotyping
Bmi-1
+/2 mice (129Ola/FVB/N hybrid background) that were
backcrossed 10–12 times onto a C57BL/6J background were
mated to generate 2 or 4-week-old (postnatal 14 or 28-day-old)
Bmi-1
2/2 mice and WT littermates genotyped by PCR, as
described previously [33]. This study was carried out in strict
accordance with international standards on animal welfare and the
guidelines of the Institute for Laboratory Animal Research of
Nanjing Medical University. The protocol was approved by the
Committee on the Ethics of Animal Experiments of Nanjing
Figure 3. Ultrastructural alterations of the area CA1 stratum radiatum in 4-week-old Bmi-1
2/2 mice. (A) A representative electron
micrograph showing axonal (Ax)-dendrite (De) synapses (arrowheads) in WT mice. (B) Ultrastructural architecture of synaptic areas in Bmi-1
2/2 mice.
The density of synapses decreased, and the residual synapses underwent degeneration (arrowheads). Many aberrant mitochondria (arrows) exhibited
‘‘zebra-like’’, swollen or vacuolar profile. In addition, the density of microtubules also decreased in the dendritic cytoplasm as compared with that in
the WT littermates. (C) A normal brain capillary from WT mice. Note that the capillary wall was surrounded by flattened endfeet of astrocytes (stars).
(D) Abnormal architecture of the brain capillary from Bmi-1
2/2 mice. The capillary lumen was narrowed and obstructed accompanied with the
swollen astrocyte endfeet (stars).
doi:10.1371/journal.pone.0032015.g003
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made to minimize animal suffering and to reduce the number of
animals used.
Preparation of brain sections
The mice were anesthetized with sodium pentobarbital and
transcardially perfused with 0.9% saline followed by 1%
paraformaldehyde with 1% glutaraldehyde (for conventional
electron microscopy) or 4% paraformaldehyde (for histochemistry
or immunohistochemistry) in phosphate buffer (PB, 0.1 M,
pH 7.4). The brains were dissected and postfixed overnight at
4uC. For electron microscopy, 80 mm forebrain or hippocampus
cross-sections were sliced via a vibratome. The striatum and CA1
stratum radiatum were trimmed, dehydrated and embedded in
Epon 812. Ultrathin sections of 70 nm were obtained, counter-
stained on copper grids with both uranyl acetate and lead citrate,
and examined with a Jeol 1200EX electron microscope (Tokyo,
Japan). For histochemistry or immunohistochemistry, some
sections were dehydrated in a series of graded ethanol solutions
and embedded in paraffin. Next, the coronal sections of the
forebrain or hippocampus were cut to thickness of 5 mm and
divided into six series. The remaining brain tissues were stored in
30% sucrose solution at 4uC for 48 h, and cut transversely on a
freezing microtome at 40 mm thickness (Leica, Nussloch, Ger-
many). The sections were collected in six series and used for Iba-1
immunostaining.
Toluidine blue staining
Paraffin-bedded forebrain sections were stained in 0.5%
toluidine blue for 10 minutes after dewaxing and rehydration.
Following a distilled water wash, the sections were dehydrated
through a graded series of alcohol and vitrificated in xylene.
Immunohistochemical staining
The protocol for immunohistochemisty was as described
previously [47]. Briefly, sections were incubated with the primary
antibody as following: mouse anti-GFAP (1:1500, Sigma-Aldrich,
Saint Louis, MO, USA), rabbit anti-caspase-3 (1:1500, Millipore,
Billerica, MA, USA), guinea pig anti-GLT-1 (1:1000, Millipore),
guinea pig anti-GLAST (1:1000, Millipore), rabbit anti-GS (1:200,
Santa Cruz BioTech, Santa Cruz, CA, USA), rabbit anti-Iba-1
(1:500, Wako, Wako, Osaka, Japan), mouse anti-synaptophysin
(1:1200, Sigma-Aldrich) or mouse anti-b-tubulin III (1:2000,
Sigma-Aldrich) at 4uC overnight. After rinsing in PBS, the sections
were incubated with biotinylated goat anti-rabbit (1:200), mouse
(1:200) or guinea pig (1:200) IgG for 1 h at room temperature and
visualized using Elite ABC Kit (Vector, Burlingame, CA, USA).
Quantitative analysis of immunostaining
The number of GFAP positive astrocytes per striatum or
hippocampus cross-section was counted at a magnification of
6100 using a digital microscope (Leica Microsystems, Wetzlar,
Figure 4. Demyelination in the striatum of 4-week-old Bmi-1
2/2 mice. (A–D) Toluidine blue staining (A–B) and MBP immunohistochemistry
(C–D). Many fiber bundles contained vacuoles (arrowheads) in the striatum of Bmi-1
2/2 mice, but not in WT littermates. (E–F) Ultrastructure of the
myelinated axons in the striatum of WT mice (E) and Bmi-1
2/2 mice (F). Many axons underwent demyelination with stripping of the myelin lamellae
(arrows in F) in Bmi-1
2/2 mice. Some axons even totally degenerated with only empty vacuoles left.
doi:10.1371/journal.pone.0032015.g004
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were averaged to provide a mean value for each group. The
number of caspase-3 positive hippocampal neurons was also
counted by the same method. In addition, the extent of
demyelination within striatum was assessed on coronal sections
stained with Toluidine blue or MBP. The ratio of the fiber bundles
containing vacuoles to the total fiber bundles per striatum section
was analyzed. Finally, the mean integrated optical density (MIOD)
was measured to assess the expression levels of synaptophysin, b-
tubulin III, GLT-1, GLAST, and GS in the whole hippocampus
regions at a magnification of 6100, respectively, using an Image-
Pro Plus 6.0 Analysis System (Media Cybernetics Inc., San
Francisco, CA, USA) [47].
Western blotting
Proteins were extracted from the hippocampus or striatum and
quantified with a kit (Bio-Rad, Mississauga, Ontario, Canada).
Ten mg protein samples were fractionated by SDS-PAGE and
transferred to nitrocellulose membranes. The immunoblotting was
carried out as described using antibodies against with GFAP
(1:2000), GLT-1 (1:1000), GLAST (1:1000) and GS (1:200) [47].
The immunocomplexes were visualized using the ECL detection
kit (Amersham Pharmacia Biotech, Canada). Membranes were
scanned and analyzed using an Omega 16ic Chemiluminescence
Imaging System (Ultra-Lum, USA).
Biochemical measurement
The brain tissues were homogenized in cold saline. The
homogenate (10%) was centrifuged at 4000 rpm at 4uC for
10 min. The supernatant was used for measurements of hydroxyl
radical, malondialdehyde and protein carbonyl levels. All
examinations were performed according to the manufacturer’s
instructions (Jiancheng Institute of Biotechnology, China). The
detailed methods have been described in the previously published
report [48].
Statistical Analysis
Data are presented as the mean 6 SEM. Statistical comparisons
were made using the Student’s t-test, with a probability value
,0.05 being considered significant.
Figure 5. Reactive astrogliosis in the brain of 4-week-old Bmi-1
2/2 mice. (A–B) Immunostaining for GFAP in the coronal sections of the
striatum and hippocampus. Activated astrocytes with hypertrophic cell bodies and intensely stained processes were present in Bmi-1
2/2 mice.
(C) Bmi-1
2/2 mice showed a higher number of GFAP positive astrocytes per coronal section of the striatum (786672.4 vs. 183628.69) and
hippocampus (626638.7 vs. 515622.89) compared with WT controls. Five mice per genotype and 3 sections per mouse. (D) Bmi-1
2/2 mice showed
increases in relative protein expression levels of GFAP in the striatum (11.0960.59 vs. 160.22) and hippocampus (1.6360.22 vs. 160.16) compared
with WT controls. Three mice per genotype and 3 independent experiments for each homogenized brain sample. Data are expressed as mean 6 SEM.
*P,0.05 vs. WT mice.
doi:10.1371/journal.pone.0032015.g005
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2/2 mice. Compared with WT littermates (A and C), strong
immunostaining for the microglial marker Iba-1 was observed in the hippocampus of Bmi-1
2/2 mice (B and D). Activated microglia with large soma
and thick processes (arrowheads) were present at Bmi-1
2/2 mice (D).
doi:10.1371/journal.pone.0032015.g006
Figure 7. Decreased expression of GLT-1, GLAST and GS in the hippocampus of 4-week-old Bmi-1
2/2 mice. (A–B) Representative
micrographs showing immunoreactivities of GLT-1, GLAST and GS in the dentate gyrus of the two genotype mice. (B) Semi-quantitative analysis
showed lower mean integrated optical densities (MIOD) of immunostainings for GLT-1 (0.7160.07 vs. 160.1), GLAST (0.7860.06 vs. 160.07) and GS
(0.4760.1 vs. 160.12) in the hippocampus of Bmi-1
2/2 mice compared with WT controls. Five mice per genotype and 3 hippocampal sections per
mouse. (C) Western blotting showed decreases in protein expression levels of GLT-1 (0.5460.06 vs. 160.12), GLAST (0.6560.07 vs. 160.08) and GS
(0.5860.1 vs. 160.1) in the hippocampus of Bmi-1
2/2 mice compared with WT controls. Three mice per genotype and 3 independent experiments for
each homogenized brain sample. Data represent means 6 SEM. *P,0.05; vs. WT mice.
doi:10.1371/journal.pone.0032015.g007
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Figure S1 Oxidative parameters in 2-week-old Bmi-1
2/2
mice and wild-type controls. Brain tissues from Bmi-1
2/2
mice showed higher levels of hydroxyl radical (93.8267.54 vs.
62.8166.35 U/mg protien; A), protein carbonyl (3.7360.25 vs.
3.4760.22 nmol/mg protein; B) and malondialdehyde (3.2260.25
vs. 2.9960.23 nmol/mg protein; C) than those from WT controls,
but the significant difference was only hydroxyl radical levels. Five
mice per genotype and 3 independent experiments for each
homogenized brain sample. Data are expressed as mean 6 SEM.
*P,0.05 vs. WT mice.
(TIF)
Figure S2 Immunohistochemistry for MBP in the
striatum of 2-week-old Bmi-1
2/2 mice and wild-type
controls. (A–D) The distributional pattern of MBP positive fibers
bundles within the striatum was similar between the two genotype
mice, although MBP immunostaining was weaker in Bmi-1
2/2
mice.
(TIF)
Figure S3 Expression of GLT-1, GLAST and GS in the
hippocampus of 2-week-old Bmi-1
2/2 mice and wild-
type controls. (A) Representative micrographs showing immu-
noreactivities of GLT-1, GLAST and GS in the hippocampal CA1
region of the two genotype mice. (B) Semi-quantitative analysis
showed that there were no significant differences in the mean
integrated optical densities (MIOD) of immunostainings for GLT-
1 (0.8860.15 vs. 160.12), GLAST (0.9460.1 vs. 160.11) and GS
(1.0460.16 vs. 160.12) in the hippocampus of Bmi-1
2/2 mice
and WT controls. Five mice per genotype and 3 hippocampal
sections per mouse. (C) There were no significant differences in
protein expression levels of GLT-1 (0.9460.14 vs. 160.12),
GLAST (0.960.15 vs. 160.11) and GS (0.9760.11 vs. 160.07) in
the hippocampus of Bmi-1
2/2 mice and WT controls. Three mice
per genotype and 3 independent experiments for each homoge-
nized brain sample. Data represent means 6 SEM. *P,0.05 vs.
WT mice.
(TIF)
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